Alvarez-Vallina L - Search Results

1

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.

Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Hernández-Pérez S, Merino N, Bonet J, Navarro R, Van Bergen En Henegouwen PMP, Lykkemark S, Mikkelsen K, Mølgaard K, Jabs F, Sanz L, Blanco FJ, Roda-Navarro P, Alvarez-Vallina L. Harwood SL, et al. Oncoimmunology. 2017 Sep 27;7(1):e1377874. doi: 10.1080/2162402X.2017.1377874. eCollection 2017. Oncoimmunology. 2017. PMID: 29296540 Free PMC article.

2

Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy.

Sanz L, Kristensen P, Russell SJ, Ramirez García JR, Alvarez-Vallina L. Sanz L, et al. Cancer Immunol Immunother. 2001 Dec;50(10):557-65. doi: 10.1007/s00262-001-0235-5. Cancer Immunol Immunother. 2001. PMID: 11776378 Free PMC article.

3

Development of a computer-assisted high-throughput screening platform for anti-angiogenic testing.

Sanz L, Pascual M, Muñoz A, González MA, Salvador CH, Alvarez-Vallina L. Sanz L, et al. Microvasc Res. 2002 May;63(3):335-9. doi: 10.1006/mvre.2001.2389. Microvasc Res. 2002. PMID: 11969310

4

Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices.

Sanz L, Kristensen P, Blanco B, Facteau S, Russell SJ, Winter G, Alvarez-Vallina L. Sanz L, et al. Gene Ther. 2002 Aug;9(15):1049-53. doi: 10.1038/sj.gt.3301725. Gene Ther. 2002. PMID: 12101437

5

A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis.

Sanz L, García-Bermejo L, Blanco FJ, Kristensen P, Feijóo M, Suárez E, Blanco B, Alvarez-Vallina L. Sanz L, et al. EMBO J. 2003 Apr 1;22(7):1508-17. doi: 10.1093/emboj/cdg150. EMBO J. 2003. PMID: 12660158 Free PMC article.

6

Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells.

Sanz L, Feijóo M, Blanco B, Serrano A, Alvarez-Vallina L. Sanz L, et al. Cancer Immunol Immunother. 2003 Oct;52(10):643-7. doi: 10.1007/s00262-003-0400-0. Epub 2003 Jun 19. Cancer Immunol Immunother. 2003. PMID: 12827304 Free PMC article.

7

The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies.

Sanz L, Alvarez-Vallina L. Sanz L, et al. Trends Mol Med. 2003 Jun;9(6):256-62. doi: 10.1016/s1471-4914(03)00070-4. Trends Mol Med. 2003. PMID: 12829014

8

Antibodies and gene therapy: teaching old 'magic bullets' new tricks.

Sanz L, Blanco B, Alvarez-Vallina L. Sanz L, et al. Trends Immunol. 2004 Feb;25(2):85-91. doi: 10.1016/j.it.2003.12.001. Trends Immunol. 2004. PMID: 15102367 Review.

9

Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all?

Sanz L, Qiao J, Vile RG, Alvarez-Vallina L. Sanz L, et al. Curr Gene Ther. 2005 Feb;5(1):63-70. doi: 10.2174/1566523052997479. Curr Gene Ther. 2005. PMID: 15638711 Review.

10

Antibody engineering: facing new challenges in cancer therapy.

Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Sanz L, et al. Acta Pharmacol Sin. 2005 Jun;26(6):641-8. doi: 10.1111/j.1745-7254.2005.00135.x. Acta Pharmacol Sin. 2005. PMID: 15916728 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112 results

Search Page

Filters